ArticleAlimentary pharmacology & therapeutics2026
Very Early-Stage Detection Is Associated With Improved Survival in Patients With Unifocal Hepatocellular Carcinoma.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimsThe goal of hepatocellular carcinoma (HCC) surveillance is to improve early HCC detection; however, the incremental benefits of detection of T1a tumours compared to T1b tumours are unclear. We aimed to evaluate the survival of patients with HCC detected at a T1a stage compared to T1b stage.
methodsWe conducted a multicentre retrospective study of adult patients from three sites in the United States who were newly diagnosed with unifocal HCC (based on LIRADS v2018), measuring between 1.0 and 3.0 cm at diagnosis between July 2013 and November 2022. All patients were required to have Child-Turcotte-Pugh (CP) class A or B cirrhosis and undergo timely treatment within 90 days of diagnosis. Multivariable Cox proportional hazard models were used to evaluate associations between tumour size (T1a vs. T1b) and overall survival and transplant-free survival.
resultsOf 140 eligible patients (median age 67 years, 72% male), 88 had T1a and 52 had T1b HCC. Median overall survival was 5.5 (95% CI: 3.79-NE (Not Evaluable)) years for patients with T1a HCC versus 3.1 (95% CI: 2.52-4.63) years for those with T1b HCC (p = 0.019). In multivariable analysis, mortality was significantly associated with Child Pugh B (vs. Child Pugh A; HR: 2.362; 95% CI: 1.39-4.93), higher logarithm transformed AFP (HR: 1.42; 95% CI: 1.20-1.69) and lesion size in cm (HR: 2.95; 95% CI: 1.69-5.16).
conclusionsDetection of HCC at a T1a stage conveys a survival advantage compared to T1b stage, underscoring a continued need for improvements in HCC surveillance efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.